Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: a case report.
Academic Article
Publication Date:
2013
Short description:
Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: a case report / Nucera, G; Mandato, Vd; Gelli, Mc; Palomba, S; La Sala, Giovanni Battista. - In: GYNECOLOGICAL ENDOCRINOLOGY. - ISSN 0951-3590. - ELETTRONICO. - 29:3(2013), pp. 219-221. [10.3109/09513590.2012.738726]
abstract:
Background: A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing. Case: A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up. Conclusion: GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.
Iris type:
Articolo su rivista
Keywords:
levonorgestrel-intrauterine device; IVF
List of contributors:
Nucera, G; Mandato, Vd; Gelli, Mc; Palomba, S; La Sala, Giovanni Battista
Published in: